Results 11 to 20 of about 227,291 (309)

Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?

open access: yesRadiation Oncology, 2022
Introduction The first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at ...
Thomas Charleux   +8 more
doaj   +1 more source

Adjuvant Radiotherapy Improved Survival in Stage I to II Low-Grade Endometrial Stromal Sarcoma: A Retrospective Study of 152 Cases

open access: yesFrontiers in Oncology, 2021
ObjectiveLow-grade endometrial stromal sarcoma (LG-ESS) is a rare gynecological tumor. Whether adjuvant radiotherapy benefits survival in patients with resected early-stage ESS remains controversial.
Wenhui Wang   +5 more
doaj   +1 more source

Adjuvant radiotherapy for cutaneous melanoma [PDF]

open access: yesCancer, 2008
AbstractThe purpose of the current study was to discuss the efficacy of adjuvant radiotherapy (RT) in the treatment of melanoma by reviewing the pertinent literature. The risk of locoregional recurrence after surgery alone for locally advanced melanoma is relatively high.
William M, Mendenhall   +6 more
openaire   +2 more sources

Tumor location as an indication for adjuvant radiotherapy in pT3N0 rectal cancer after surgery

open access: yesRadiation Oncology, 2019
Background The optimal care for pT3N0 rectal cancer remains controversial. And whether tumor location can be used to guide the administration of adjuvant radiotherapy for pT3N0 rectal cancer is not fully confirmed.
Hai-hua Peng   +4 more
doaj   +1 more source

External radiotherapy of thyroid cancer [PDF]

open access: yes, 2001
Differentiated thyroid cancer comprises papillary, mixed papillary-follicular and follicular adenocarcinomas. They are mostly hormone-sensitive and respond to thyroid-stimulating hormone (TSH) suppression. The standard treatment is total thyroidectomy. I-
Dühmke, Eckhart, Pollinger, B.
core   +1 more source

Analysis of the efficacy and factors influencing survival of adjuvant radiotherapy for stage II-III biliary tract carcinoma

open access: yesWorld Journal of Surgical Oncology, 2023
Background To determine the efficacy of adjuvant radiotherapy for stage II–III biliary tract carcinoma. Methods We retrospectively analyzed the data of 37 patients who underwent radical resection of biliary tract carcinomas at the Affiliated Hospital of ...
Yan-Ling Guo   +3 more
doaj   +1 more source

Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy [PDF]

open access: yes, 2014
Background: After breast-conserving radiation therapy most patients experience acute skin toxicity to some degree. This may impair patients' quality of life, cause pain and discomfort. In this study, we investigated treatment and patient-related factors,
De Langhe, Sofie   +9 more
core   +2 more sources

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer : a phase II trial [PDF]

open access: yes, 2017
Background: Neo-adjuvant chemotherapy followed by radical cystectomy with extended pelvic lymph node dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC).
De Meerleer, Gert   +7 more
core   +1 more source

Determining the survival benefit of postoperative radiotherapy in patients with pT1-3N1M0 rectal cancer undergoing total mesorectal excision: a retrospective analysis

open access: yesBMC Gastroenterology, 2023
Background The National Comprehensive Cancer Network guidelines recommend routine postoperative adjuvant radiotherapy and chemotherapy for patients with stage III rectal cancer who do not receive neoadjuvant therapy before surgery.
Jin-hu Chen, Qing Ye, Feng Huang
doaj   +1 more source

Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma [PDF]

open access: yes, 2019
BACKGROUND: Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection.
Acker, Güliz   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy